Searched for
ANTI OBESITY DRUG
India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Novo Nordisk signs deal with OpenAI to develop new drugsDanish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partn...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
- ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears riseTirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts c...
- Cipla eyes entry into India's weight management market amid rising demand and global competitionCipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...
- India's anti-obesity drug market has grown more than fourfold in the last five yearsIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle di...
- India’s anti-obesity drug market quadruples in five years on lifestyle disease surgeIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- Anti-obesity drug market gaining traction in IndiaAccording to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...
- Corona inks agreement with Kitozyme for a fat binder anti-obesity drugBelgium life science company, Kitozyme entered into in-licensing agreement with Corona Remedies for fat binder anti-obesity drug.
- Centre bans anti-obesity drug due to side effectsThe government has banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands d...
- Pharmas gain from your weightYour fat loss is revenue gain for pharma companies. As obesity is fast becoming major concern in developing countries, sales of lifestyle r...
Load More
